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Abstract
Lately, understanding the role of cancer stem cells in tumor
initiation and progression became a major focus in stem cell
biology and in cancer research. Considerable efforts, such as the
recent studies by Honeth and colleagues, published in the June
issue of Breast Cancer Research, are directed towards developing
clinical applications of the cancer stem cell concepts. This work
shows that the previously described CD44+CD24- stem cell
phenotype is associated with basal-type breast cancers in human
patients, in particular BRCA1 inherited cancers, but does not
correlate with clinical outcome. These very interesting findings
caution that the success of our efforts in translating cancer stem
cell research into clinical practice depends on how thorough and
rigorous we are at characterizing these cells.
The cancer stem cell model, a concept initially proposed
more than a century ago, has been revisited with increasing
enthusiasm in the past decade. This model proposes that
tumors, like normal tissues, are organized in a cellular
hierarchy, in which ‘cancer stem cells’ are the only cells with
unlimited proliferation potential and therefore capable of
driving tumor growth and metastasis. The ‘differentiated’
cancer cells that account for the majority of the tumor
population may have high proliferation potential, but it is not
unlimited. It follows that eliminating these differentiated
progenies while sparing the cancer stem cells will ultimately
result in relapse. The other component of the stem cell model
of carcinogenesis holds that stem and progenitor cells are
the cells susceptible to transformation, owing to their long life
and high proliferative capacity.
A paradigm-shifting hypothesis, the cancer stem cell model
could potentially be the foundation for new preventive and
therapeutic strategies in cancer. However, concerns regard-
ing the validity of this model have been expressed, mostly
regarding its experimental validation. It has been brought to
attention that xenografting cancer cells in immunosupressed
animals, the gold standard for testing cancer stem cell
properties in vivo, may select for cells adaptable to the animal
host, therefore introducing an unavoidable bias. Experts in the
field cautioned against oversimplified views that do not take
into account the genetic variability and clonal evolution of
cancer cells, including those of cancer stem cells.
The efforts of numerous recent studies focused on testing the
validity and universality of this model across tumor types of
various tissues, and on exploring its clinical implications. In
line with these directions, the recent study by Honeth and
colleagues [1] aims to identify possible correlations between
the representation of tumor-initiating cells and classic
molecular and histoclinical parameters that classify breast
cancer in several distinct subtypes: basal, luminal A and B,
HER2 positive and normal-like. Associations between
presence of cancer stem cells in clinical samples, aggressive
tumor behavior and poor clinical outcome have been
speculated upon, but so far only one study shows such an
association in breast cancer patients [2]. Honeth and
colleagues [1] used the CD44+ CD24- phenotype to identify
breast tumor initiating cells. This tumor initiating phenotype
was proposed by Clarke and colleagues [3], who provided
the first proof of principle for the existence of cancer stem
cells in solid tumors. Their study showed that in nine breast
cancer samples, a minority of cells bearing the surface
markers CD44+CD24- (negatively selected for eight lineage
markers in order to eliminate non-epithelial cells), were
capable of generating tumors in NOD/scid mice even when
implanted in low numbers. By contrast, the other cancer cell
populations, such as CD44+CD24+, failed to generate
tumors even when implanted in high numbers.
This ground breaking work had tremendous impact in both
the stem cell field and in cancer research. At this point, it is of
paramount importance to investigate the universality of these
new concepts. Given the small number of tumors analyzed in
the study by Clarke and colleagues [3] and the character-
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istics of these tumors (eight out of nine were pleural
effusions), it is critical to inquire if the findings apply to a
larger number of tumors that cover the diversity of breast
cancer subtypes. Whereas the study from Hegardt’s group
[1] is correlative in nature, the use of a large collection of well
characterized breast cancers gives weight to their
conclusions. Overall, only 31% of the tumors analyzed
contained CD44+CD24- cells, ranging from 1% or less to
100% of the total tumor population. The CD44+CD24-
phenotype was more common in basal-like tumors, and
strongly associated with BRCA1 hereditary breast cancers.
Given the large representation of CD44+CD24- cells in the
basal layer of normal breast epithelium, these findings
suggest that the cellular origin of the basal breast cancers
may be a progenitor of the basal lineage. This is also
consistent with the recently proposed role of BRCA1 in
luminal differentiation [4]. Alternatively, or in addition, a block
in luminal differentiation may lead to the same basal-like
molecular phenotype, which often contains CD44+CD24-
cells. However, not all basal breast tumors and very few
HER2 positive tumors had CD44+CD24- cells. Consistent
with previous work from two other groups, the presence of
CD44+CD24- cells in breast tumors did not correlate with
clinical outcome [5,6]. No association between the
CD44+/CD24- status and markers known to be important for
the clinical outcome, such as tumor size, lymph node status
or S-phase fraction was observed.
The findings of Honeth and colleagues raise several
important questions. Some pertain to the universality of the
cancer stem cell phenotype. Is the CD44+CD24- phenotype
associated with tumor initiating cells only in certain breast
cancers, predominantly basal-like or BRCA1? Are cancers
that do not contain cells with this phenotype driven by a
different cancer stem cell? If this is the case, do these cancer
stem cells not bearing the CD44+CD24- phenotype have a
different origin? One could speculate that they are derived
from luminal progenitor cells that, upon transformation, give
rise to breast cancers with these predominant molecular
traits.
Other markers, such as the ALDH1 breast cancer stem cell
marker, which is also present in only about 30% of tumors,
can further divide the CD44+CD24-lin- cell population into
fractions that are highly tumorigenic: ALDH+CD44+CD24-
lin-, which is capable of generating tumors from 20 cells; and
ALDH-CD44+CD24-lin-, which are not tumorigenic. Unlike
CD44+CD24-lin-, the ALDH1 phenotype correlates with
clinical outcome and certain histoclinical characteristics, such
as tumor grade, HER2 positivity, and Ki67 status, although it
is not associated with a particular molecular subtype of
breast cancer [2] .
Other questions that can be raised pertain to the cancer stem
cell model itself. Is it possible that the CD44+CD24-
phenotype is a dynamic one, and can it be lost and re-
acquired during tumor progression, as a result of genetic
instability and epigenetic changes? The initial findings of
Clarke and colleagues indicate that this may not be the case,
since in as many as four consecutive passages the hierarchy
defined by the CD44+ CD24-lin- phenotype was maintained.
However, recent studies show that the CD44+CD24-
phenotype can be induced by genetic events, such as Twist
overexpression, or epigenetic events, such as exposure to
transforming growth factor beta, a factor secreted by tumor
associated stroma [7]. Moreover, whereas the initial work
from Clarke’s group described CD44 as a marker of stem
cells, subsequent studies from other groups demonstrated
that CD44 is functionally involved in both tumor initiation and
tumor progression [7].
As Honeth and collegues conclude [1], there is much to be
uncovered about cancer stem cells and their role in
carcinogenesis and one should not yet exclude the
coexistence of clones of independent origin and evolution,
within the entire tumor population or within the cancer stem
cell fraction. Whereas the stochastic model of carcino-
genesis and the cancer stem cell model are exclusive, it is
clear that clonal evolution contributes to the heterogeneity of
cancers, even if they are hierarchically organized. Regardless
of these conceptual considerations, developing clinical
applications based on cancer stem cell concepts is still an
ongoing effort that, despite numerous challenges, has
tremendous promise.
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